The Assessment of Nicorandil Effect on the Quality of Life in Patients With Stable Angina in the "Kvazar" Study

Martsevich, S. Yu.; Кутишенко, Н. П.; Деев, А. Д.

doi:10.20996/1819-6446-2016-12-6-654-660

Cited by 5 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Современная стандартная медикаментозная терапия стабильной стенокардии способна, по некоторым данным, значительно уменьшить проявления болезни, однако это не всегда влечет за собой достаточное улучшение качества жизни (Marcevich et al, 2016;Tendera et al, 2016). Аналогичные результы получены в нашем исследовании.…”

Section: Discussionunclassified

Improving the quality of life of patients with stable angina pectoris using combined therapy

Zolotarova

2017

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

Treatment of chronic ischemic heart disease includes the use of non-drug methods (anti-hypodynamia, smoking cessation, etc.), as well as drug therapy, the main tasks of which are to reduce the risk of complications such as stroke, myocardial infarction, sudden cardiac death, and to gain an increase in life expectancy. An important aspect of treatment is also a decrease in the frequency and intensity of angina attacks, the need for short-acting nitrates, to gain an increase in physical activity, that is, an overall, improvement in the quality of life of patients. The article presents the results of studying the quality of life indicators of patients with stable angina pectoris with the use of omega-3 polyunsaturated fatty acids and magnetotherapy. 85 patients with stable angina pectoris were examined, divided into three groups according to the method of therapy. 28 patients of the I (control) group received a drug complex corresponding to the national protocol for the treatment of patients with angina pectoris: nitrates, beta-blockers, ACE inhibitors, antiplatelet drugs, statins (atorvastatin at a daily dose of 20 mg). 29 patients of the II group, together with protocol therapy, received the drug omega-3 polyunsaturated fatty acids in a daily dosage of 2000 mg, divided into 2 doses. In connection with the known hypolipidemic action of omega-3 PUFA, the daily dose of atorvastatin in this and the next group was reduced to 10 mg. Group III consisted of 28 patients who were prescribed omega-3 polyunsaturated fatty acids and a course of magnetotherapy according to a special method against the background of the protocol medication complex. It was revealed that, initially in patients with angina, the quality of life indicators according to the Seattle questionnaire and the visual analogue scale were reduced. It was shown that with the use of the protocol medication complex, all the parameters of the quality of life improved reliably, with a significant reduction in the angina pain scales and less significant improvement on the scales of physical activity, assessments of health and the perception of the disease . Upon adherence to the therapy of omega-3 polyunsaturated fatty acids, there was a positive but very weak tendency to improve the quality of life indicators, which did not differ significantly from the control. The use of combined therapy with simultaneous inclusion of omega-3 polyunsaturated fatty acids and magnetotherapy led to significant and reliable improvement in the quality of life indicators, not only on the scales reflecting the pain component, but also on the indicators that characterize the psychological contribution to the quality of life (treatment satisfaction and quality of life (disease perception)). The significant improvement in the quality of life in patients receiving magnetotherapy in contrast to the absence of such influence in patients receiving omega-3 polyunsaturated fatty acids without magnetotherapy was due to the strong antianginal effect of MT, its sedative and emotionally relaxing action, and the ability to enhance the effects of medications.

show abstract

Section: Discussionunclassified

Improving the quality of life of patients with stable angina pectoris using combined therapy

Zolotarova

2017

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

“…При включении в исследование (1-я неделя) и на последнем визите (10-я неделя) участники отвечали на вопросы SAQ [9][10][11]. SAQ состоит из 5 оценочных шкал, посвященных различным аспектам ИБС: шкала ограничений физических нагрузок, стабильности приступов стенокардии, частоты приступов стенокардии, удовлетворенности лечением и отношения к болезни [9].…”

Section: материал и методыunclassified

The effect of rivaroxaban low doses on the stable angina of the II–III functional class clinical manifestations and the quality of life in patients with ischemic heart disease

Некрасов

Timoshchenko²,

Некрасова

et al. 2021

Kardiologiia

View full text Add to dashboard Cite

Aim To evaluate the effect of low-dose rivaroxaban on quality of life of patients and clinical manifestations of functional class (FC) II-III stable angina.Material and methods 26 patients with ischemic heart disease (IHD) with FC II-III stable angina, who were newly prescribed rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg, were followed for 10 weeks. During the first (before the beginning of treatment) and the last weeks of study, patients kept diaries, in which they reported angina attacks and short-acting nitrate intake, filled in an angina questionnaire (SAQ), and underwent electrocardiogram (ECG) Holter monitoring (HM).Results The treatment was associated with decreases in the frequency of angina attacks (by 19.5 %; р=0.027) and the number of taken short-acting nitrate pills (by 17.1 %; р=0.021) and an improvement of quality of life according to stability scales (р=0.042). Data from ECG HM showed decreases in the number and duration of ischemic episodes (p≤0.05).Conclusion The treatment of IHD patients with rivaroxaban 2.5 mg twice a day in combination with acetylsalicylic acid 75-100 mg for 2 mos. was associated with decreased frequency of angina attacks, reduced requirement for short-acting nitrate, and with improvement of quality of life.

show abstract

“…Очевидно, что пациенты, приверженные и неприверженные к приему никорандила, отличались между собой по ряду признаков, в первую очередь -по тяжести стенокардии. Вполне объяснимо, что более приверженные к приему никорандила больные имели более тяжелое течение стенокардии, что объясняется наличием у препарата очевидного антиангинального эффекта, подтвержденного и результатами других исследований [12][13][14].…”

Section: результатыunclassified

The First Results of the Evaluation of Long-Term Nicorandil Treatment Effect on the Probability of Cardiovascular Complications in Patients with Stable Coronary Artery Disease (Data of Observational NIKEA Study)

Martsevich

Lukina

Кутишенко

et al. 2019

Racionalʹnaâ farmakoterapiâ v kardiologii

Self Cite

View full text Add to dashboard Cite

Aim. To assess the influence of addition of nicorandil on long-term cardiovascular complications in patients with chronic coronary artery disease (CAD) in the framework of a prospective observational study.Material and methods. Prospective observational multicenter NIKEA study included 590 patients with stable CAD. All patients were recommended to add nicorandil to their baseline therapy. After 21 months, 547 telephone contacts were made, the life status of 524 people was specified, 23 patients were lost to follow-up. The following complications were registered: death from any cause; non-fatal myocardial infarction (MI); non-fatal stroke; urgent myocardial revascularization; hospitalization due to deterioration of CAD, chronic heart failure (CHF) or atrial fibrillation (AF). In 479 patients, a telephone survey was performed to identify adherence (persistence) to nicorandil– i.e. to verify the continuing the treatment for the prescribed duration.Results. During the follow-up period, 15 deaths were recorded, the causes of which were as follows: 3 CAD (2 MI, 1 left ventricular aneurysm), 1 pulmonary embolism, 2 CHF; 1 stroke, 1 oncology, 1 bilateral pneumonia. In the remaining 6 cases, the causes of death were not known. Cardiovascular (CV) complications were MI (8 cases in 7 patients, 1 patient had 2 MI in the follow-up period, 3 patients from this group died), stroke in 6 patients (7 cases, 1 patient had 2 strokes, 1 patient died). Urgent percutaneous coronary intervention was performed in 3 patients (in 2 patients due to acute MI, in 1 patient due to unstable angina). During the observation period, 21 people were urgently hospitalized due to deterioration of clinical condition. According to the results of a medical survey, by the end of the follow-up period, 237 people were not adherent to prescribed nicorandil, and 242 patients took the recommended medication (adherent patients). The main cardiovascular complications and death from any cause (р<0.001) as well as the number of urgent hospitalizations (р=0.017) were significantly more common in non-adherent to nicorandil patients in comparison with adherent patients.Conclusion. The overall rate of CAD complications in NIKEA study was typical for patients with stable CAD receiving contemporary medical therapy. Addition of nicorandil significantly reduced the rate of CV complications in adherent patients in comparison with non-adherent patients.

show abstract

The Assessment of Nicorandil Effect on the Quality of Life in Patients With Stable Angina in the "Kvazar" Study

Cited by 5 publications

References 12 publications

Improving the quality of life of patients with stable angina pectoris using combined therapy

Improving the quality of life of patients with stable angina pectoris using combined therapy

The effect of rivaroxaban low doses on the stable angina of the II–III functional class clinical manifestations and the quality of life in patients with ischemic heart disease

The First Results of the Evaluation of Long-Term Nicorandil Treatment Effect on the Probability of Cardiovascular Complications in Patients with Stable Coronary Artery Disease (Data of Observational NIKEA Study)

Contact Info

Product

Resources

About